ClinicalTrials.gg
RecruitingNCT02265770SIOP-EP-IIUpdated Apr 26, 2024

An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma

A Phase 2/3 interventional study of 16 weeks of VEC + CDDP and VEC + HD-MTX in Childhood Ependymoma, sponsored by Centre Leon Berard. Recruiting at 40 sites in 15 countries. Open to participants aged Up to 22 Years. Per ClinicalTrials.gov, last updated 2024-04-26.

Sponsored by Centre Leon Berard · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2015; still recruiting 11 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
536
Allocation
Randomized
Ages
Up to 22 Years
Sex
All
01

Study summary

The overall aim of this project is to improve the outcome of patients diagnosed with ependymoma by improving and harmonising the staging and the standard of care of this patient population and to improve the investigators understanding of the underlying biology thereby informing future treatment.

The program will evaluate new strategies for diagnosis (centralized reviews of pathology and imaging) and new therapeutic strategies in order to develop treatment recommendations.

Patients will be stratified into different treatment subgroups according to their age, the tumour location and the outcome of the initial surgery. Each subgroup will be studied in a specific randomised study to evaluate the proposed therapeutic strategies.

Stratum 1:

The aim of the stratum 1 is to evaluate the clinical impact of 16-week chemotherapy regimen with VEC-CDDP following surgical resection and conformal radiotherapy in terms of progression free survival in patients who are > 12 months and \< 22 years at diagnosis, with completely removed intra cranial Ependymoma.

Stratum 2:

This stratum is designed as a phase II trial for patients who are > 12 months and \< 22 years at diagnosis, with residual disease to investigate the possible activity of HD-MTX by giving to all patients the benefit of VEC chemotherapy whilst randomising half of patients to receive additional HD-MTX.

Patients will receive conformal radiotherapy (cRT). For patients who remain with a residual inoperable disease after induction chemotherapy and cRT, an 8 Gy boost of radiotherapy to the residual tumour will be delivered immediately after the end of the cRT.

Stratum 3 This stratum is designed as a phase II trial to evaluate the benefit of postoperative dose intense chemotherapy administered alone or in combination with valproate in children \<12 months of age or those not eligible to receive radiotherapy .

Read the detailed description

The Ependymoma Program is a comprehensive program to improve the accuracy of the primary diagnosis of ependymoma and explore different therapeutic strategies in children, adolescents and young adults, accordingly. This program is opened to all patients diagnosed with ependymoma below the age of 22 years.

It will include a centralised review of pre and post-operative imaging to assess the completeness of the resection.

It will also include a central review of pathology to confirm the histological diagnosis. The biological markers 1q and 6q gain, Tenascin C status, NELL2 and LAMA2, RELA-fusion and molecular subgroup by methylation array will be prospectively assessed for prospective evaluation of disease subgroups. Further biological evaluations will be coordinated within the linked BIOMECA study.

After surgery and central review of imaging and pathology, patients will be offered the opportunity to undergo second look surgery, if possible. Patients will be enrolled in one of 3 different strata according to the outcome of the initial surgical resection (residual disease vs no residual disease), their age or eligibility / suitability to receive radiotherapy. These 3 different strata correspond to 3 therapeutic strategies according to the patient status.

  1. Stratum 1 is designed as a randomised phase III study for patients who have had a complete resection, with no measurable residual disease (as confirmed by centrally reviewed MRI) and are > 12 months and \< 22 years at diagnosis. Those patients will be randomised to receive conformal radiotherapy followed by either 16 weeks of chemotherapy with VEC-CDDP, or observation.
  2. Stratum 2 is designed as a randomised phase II study for patients who have inoperable measurable residual disease and who are > 12 months and \< 22 years at diagnosis. Those patients will be randomised to two different treatment schedules of chemotherapy either with VEC or VEC+ high dose methotrexate (VEC +HD-MTX). After completion of the frontline chemotherapy, patients will be assessed for response (MRI) and will receive second look surgery when feasible. For those patients who remain unresectable with residual disease despite frontline chemotherapy and for whom second line surgery is not feasible, there will be a study of the safety of a radiotherapy boost of 8 Gy that will be administered to the residual tumour immediately after the completion of the conformal radiotherapy. Patients without evidence of residual disease after the chemotherapy and/or a second look surgery are not eligible for radiotherapy boost. All patients who have not shown progression under chemotherapy will receive, as maintenance therapy, a 16 week course of VEC -CDDP following completion of radiotherapy.
  3. Stratum 3 is designed as a randomised phase II chemotherapy study in children \<12 months of age or those not eligible to receive radiotherapy. These patients will be randomised to receive a dose dense chemotherapy alternating myelosuppressive and relatively non-myelosuppressive drugs at 2 weekly intervals, with or without, the addition of the histone deacetylase inhibitor, valproate.

Registry: Patients that do not fulfil the inclusion criteria of one of the interventional strata will be enrolled and followed up via an observational study which will be analysed descriptively.

02

Conditions studied

  • Childhood Ependymoma
03

In context

Lead sponsor

Centre Leon Berard is the lead sponsor of 211 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 22 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

After Initial surgery, patients will be enrolled in one of 3 different interventional strata where they will be offered a set of therapeutic interventions based on the outcome of the intervention (no measurable residue vs residual inoperable disease), their age and/or their eligibility /suitability to receive radiotherapy.

Patients with centrally and confirmed intracranial ependymoma meeting the following criteria will be enrolled into one of interventional stratum:

  • Age \< 22 years old at diagnosis
  • Newly diagnosed intracranial ependymoma of WHO grade II-III confirmed by central pathological review
  • Post-menarchal female not pregnant or nursing (breast feeding) and with a negative beta-HCG pregnancy test prior to commencing the trial
  • Males and females of reproductive age and with effective for the duration of their treatment and 6 months after the completion of their treatment
  • No to the use if one of the study drugs proposed by the protocol
  • Patients and/or their parents or legal guardians willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedure
  • No co-existent unrelated disease at the time of study entry that would render the patient unable to receive chemotherapy
  • No signs of infection.

Common inclusion criteria for Strata 1 and 2:

  • Age > 12 months and \< 22 years at time of study entry
  • No on spinal MRI and on CSF cytology assessments
  • No previous radiotherapy
  • No previous chemotherapy (except )
  • No medical contraindication to radiotherapy and chemotherapy
  • Adequate bone marrow, liver and renal functions

Specific inclusion criteria for Stratum 1:

  • No residual measurable ependymoma based on the central neuroradiological review (R0-1-2)

Specific inclusion criteria for Stratum 2:

  • Residual non reoperable measurable ependymoma based on the central neuroradiological review (R3-4)

Inclusion criteria

Inclusion criteria for Stratum 3:

  • Children younger than 12 months at time of entry to study or any children ineligible to receive radiotherapy due to age at diagnosis, tumour location or clinician / parent decision and according to national criteria
  • Adequate bone marrow, liver and renal functions
  • No previous chemotherapy and radiotherapy
  • No contraindication to chemotherapy Patients that do not fulfill the inclusion criteria of one of the interventional strata will be enrolled and followed up into an observational study and descriptive analysis will be performed.

Exclusion criteria

EXCLUSION CRITERIA for all interventional strata:

  • Tumour entity other than primary intracranial ependymoma
  • Primary diagnosis predating the opening of SIOP Ependymoma II
  • Patients with WHO grade I ependymoma including ependymoma variants: myxopapillary ependymomas and subependymomas,patients with spinal cord location of the primary tumour
  • Participation within a different trial for treatment of ependymoma
  • to one of the IMP used according to the SmPCs
  • Concurrent treatment with any anti-tumour agents
  • Inability to tolerate chemotherapy
  • Unable to tolerate intravenous hydration
  • Pre-existing mucositis, peptic ulcer, inflammatory bowel disease ascites, or pleural effusion.

Strata 1 and 2:

  • Ineligible to receive radiotherapy
  • Patient for whom imaging remains RX despite all effort to clarify the MRI conclusion

Stratum 3:

  • Pre-existing severe hepatic and/or renal damage
  • Family history of severe epilepsy
  • Presence of previously undiagnosed mitochondrial disorder detected by screening as part of trial
  • Elevated blood ammonium and lactate level ≥ 1.5 x
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
536 participants (estimated)

Study arms

  • Experimental
    Stratum 1 arm A

    Conformal radiotherapy followed by 16 weeks of VEC + CDDP.

    Drug: 16 weeks of VEC + CDDP · Radiation: Conformal radiotherapy

  • Active comparator
    Stratum 1 arm B

    Conformal radiotherapy.

    Radiation: Conformal radiotherapy

  • Experimental
    Stratum 2 arm A

    VEC + HD-MTX followed by conformal radiotherapy +/- boost

    Drug: VEC + HD-MTX · Radiation: conformal radiotherapy +/- boost

  • Active comparator
    Stratum 2 arm B

    VEC followed by conformal radiotherapy +/- boost

    Drug: VEC · Radiation: conformal radiotherapy +/- boost

  • Experimental
    Stratum 3 arm A

    Chemotherapy + Valproate.

    Drug: Chemotherapy + Valproate

  • Active comparator
    Stratum 3 arm B

    Chemotherapy

    Drug: Chemotherapy

Interventions

  • Drug16 weeks of VEC + CDDP

    Drug page: Vincristine

    Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.

    Also known as: Vincristine, Etoposide, Cyclophosphamide, Cisplatin

  • DrugVEC + HD-MTX

    Drug page: Vincristine

    Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.

    Also known as: Vincristine, Etoposide, Cyclophosphamide, Methotrexate

  • DrugChemotherapy + Valproate

    Drug page: Valproic Acid

    Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion. Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses.

    Also known as: Vincristine, Carboplatin, Methotrexate, Cyclophosphamide, Cisplatin, Valproate

  • RadiationConformal radiotherapy

    Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.

  • DrugVEC

    D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes

    Also known as: Vincristine, Etoposide, Cyclophosphamide

  • DrugChemotherapy

    Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.

    Also known as: Vincristine, Carboplatin, Methotrexate, Cyclophosphamide, Cisplatin

  • Radiationconformal radiotherapy +/- boost

    Conformal radiotherapy: 59.4Gy (children \<18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week. In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions

06

What researchers measure

Primary outcomes

  1. Gross Total Resection rate

    Overall program, depends on the stratum (from 0.5 years to 3 years)

    Time frame: 3 years

  2. Progression-Free Survival

    Time frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 4.5 years

  3. Number of treatment responders

    Objective response to chemotherapy is measured based on SIOP-E Neuro Imaging guidelines.

    Time frame: 15 months after final patient inclusion

Secondary outcomes

  1. Number of participants undergoing a second-look surgery

    Time frame: 9 months

  2. Overall Survival

    Time frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 3 years after the final patient inclusion

  3. Quality of Survival

    Questionnaire

    Time frame: from date of randomization up to 5 years after the end of treatment

  4. Evaluation of neuropsychological morbidity

    Scores: evaluation of processing speed (WPPSI-III, WISC-IV, WAIS-IV), verbal skills (WPPSI-III, WISC-IV, WAIS-IV), fluid intelligence (WPPSI-III / Ravens, WISC-IV / Ravens, WAIS-IV / Ravens), working memory (K-ABC / Children's Memory Scale, WISC-IV, WAIS-IV), visuo-spatial abilities (Beery-Buktenica Developmental Test of Visual-Motor Integration/Wide Range Assessment of Visual Motor Abilities - WRAVMA), regarding ability (as to national policy/WIAT-II) and motoric speed (Perdue Pegboard)

    Time frame: from date of randomization up to 5 years after the end of treatment

  5. Comparison of neuroendocrine morbidity

    Weight, height and head circumference, Tanner age, early and delayed pubertal onset, blood sample analysis (evaluation of TSH, fT4, LH and FSH, oestradiol, testosterone, insulin-like growth factor 1)

    Time frame: from date of randomization up to 5 years after the end of treatment

  6. Number of participants with adverse events as a measure of safety and tolerability

    Determination of short and long term safety and toxicity of frontline chemotherapy based on proportion of patients experiencing toxicity grade 3 to 4 (adverse events)

    Time frame: from date of randomization up to 5 years after the end of treatment

  7. Radiotherapy-free survival rate

    Time frame: from date of randomization until the date of first documented progression or date of death from any cause, or radiotherapy intervention, whichever came first, up to 2.5 years after the final patient inclusion

  8. Efficacy in each molecular sub-group

    Efficacy in each molecular subtype described in terms of Progression-Free survival and Overall Survival

    Time frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to 3 years after the final patient inclusion

  9. Concordance between central and local radiological assessment of the efficacy of post-operative chemotherapy

    Proportion of patients in whom the result of the central radiological review confirms the local review

    Time frame: 15 months after final patient inclusion

07

Study locations

38 of 40 sites recruiting
08

References and documents

Publications

  • Leblond P, Massimino M, English M, Ritzmann TA, Gandola L, Calaminus G, Thomas S, Perol D, Gautier J, Grundy RG, Frappaz D. Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol. Front Neurol. 2022 Jun 2;13:887544. doi: 10.3389/fneur.2022.887544. eCollection 2022. PubMed 35720069 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2015 (actual). Primary completion is estimated for Jun 2028, 156 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2014
First posted
Oct 16, 2014
StartActual
Jun 2, 2015
Primary completionEst.
Jun 2028
CompletionEst.
Aug 2031
Last update
Apr 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02265770
Lead sponsor
Centre Leon Berard
Responsible party
Sponsor
First posted
Oct 16, 2014
Start date
Jun 2, 2015
Primary completion
Jun 2028 (estimated)
Completion
Aug 2031 (estimated)
Last update
Apr 26, 2024

Study contacts

Pierre LEBLOND, MD
Contact
pierre.leblond@lyon.unicancer.fr
+33 4 69 16 66 14
Pierre LEBLOND, MD
principal investigator · IHOP

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vincristine · Valproic Acid

Start the discussion